The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
|Articles|May 15, 2012
FDA Concludes Safety Review Of Novartis MS Drug Gilenya
Advertisement
The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple- sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.
The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.
Read the full story:
Source: Morningstar
Advertisement
Related to this article
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured patients.
A 39,669-patient French cohort found ustekinumab and IL-23 inhibitors carry the lowest infection risk among biologics.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5